Oliver Freudenreich

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. ncbi A placebo-controlled study of sildenafil effects on cognition in schizophrenia
    Donald C Goff
    Department of Psychiatry, MGH Schizophrenia Program, Freedom Trail Clinic, Massachusetts General Hospital, Harvard Medical School, 25 Staniford St, 2nd Floor, Boston, MA, 02114, USA
    Psychopharmacology (Berl) 202:411-7. 2009
  2. ncbi Training in a clozapine clinic for psychiatry residents: a plea and suggestions for implementation
    Oliver Freudenreich
    Dept of Psychiatry, Massachusetts General Hospital, Boston, MA, USA
    Acad Psychiatry 37:27-30. 2013
  3. ncbi Psychiatric polypharmacy: a clinical approach based on etiology and differential diagnosis
    Oliver Freudenreich
    Harvard Medical School, Department of Psychiatry, Massachusetts General Hospital, Boston, MA 02114, USA
    Harv Rev Psychiatry 20:79-85. 2012
  4. ncbi Initial medical work-up of first-episode psychosis: a conceptual review
    Oliver Freudenreich
    Massachusetts General Hospital Schizophrenia Program, Freedom Trail Clinic, Harvard Medical School, 25 Staniford Street, Boston, MA 02114, USA
    Early Interv Psychiatry 3:10-8. 2009
  5. ncbi The muddles of medicine: a practical, clinical addendum to the biopsychosocial model
    Oliver Freudenreich
    MGH Division of Psychiatry and Medicine, Boston, MA 02114, USA
    Psychosomatics 51:365-9. 2010
  6. ncbi Analysis of peripheral immune activation in schizophrenia using quantitative reverse-transcription polymerase chain reaction (RT-PCR)
    Oliver Freudenreich
    Schizophrenia Program, Massachusetts General Hospital, Boston, MA, United States
    Psychiatry Res 176:99-102. 2010
  7. ncbi Catatonic coma with profound bradycardia
    Oliver Freudenreich
    Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA
    Psychosomatics 48:74-8. 2007
  8. ncbi Risperidone augmentation for schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled trial
    Oliver Freudenreich
    Massachusetts General Hospital Schizophrenia Program, Freedom Trail Clinic, 25 Staniford St, 2nd Floor, Boston, MA 02114, USA
    Schizophr Res 92:90-4. 2007
  9. ncbi An approach to symptoms at the interface of medicine and psychiatry: pain, insomnia, weight loss and anorexia, fatigue and forgetfulness, and sexual dysfunction
    Oliver Freudenreich
    Harvard Medical School, 25 Shattuck Street, Boston, MA 02115, USA
    Med Clin North Am 94:1217-27, xi. 2010
  10. ncbi Psychiatric treatment of persons with HIV/AIDS: an HIV-psychiatry consensus survey of current practices
    Oliver Freudenreich
    Freedom Trail Clinic, 25 Staniford, St, Boston, MA 02114, USA
    Psychosomatics 51:480-8. 2010

Detail Information

Publications78

  1. ncbi A placebo-controlled study of sildenafil effects on cognition in schizophrenia
    Donald C Goff
    Department of Psychiatry, MGH Schizophrenia Program, Freedom Trail Clinic, Massachusetts General Hospital, Harvard Medical School, 25 Staniford St, 2nd Floor, Boston, MA, 02114, USA
    Psychopharmacology (Berl) 202:411-7. 2009
    ..In addition, neuronal nitric oxide synthase, another component of the NMDA/nitric oxide/cGMP intracellular pathway, has been reported to be dysregulated in schizophrenia patients...
  2. ncbi Training in a clozapine clinic for psychiatry residents: a plea and suggestions for implementation
    Oliver Freudenreich
    Dept of Psychiatry, Massachusetts General Hospital, Boston, MA, USA
    Acad Psychiatry 37:27-30. 2013
    ..This matters because clozapine is an important evidence-based treatment for refractory schizophrenia that remains underutilized in clinical practice...
  3. ncbi Psychiatric polypharmacy: a clinical approach based on etiology and differential diagnosis
    Oliver Freudenreich
    Harvard Medical School, Department of Psychiatry, Massachusetts General Hospital, Boston, MA 02114, USA
    Harv Rev Psychiatry 20:79-85. 2012
    ..Psychiatrists can ask themselves a Kantian question: would my way of prescribing lead to good, socially acceptable outcomes if followed by all physicians treating similar patients?..
  4. ncbi Initial medical work-up of first-episode psychosis: a conceptual review
    Oliver Freudenreich
    Massachusetts General Hospital Schizophrenia Program, Freedom Trail Clinic, Harvard Medical School, 25 Staniford Street, Boston, MA 02114, USA
    Early Interv Psychiatry 3:10-8. 2009
    ..To help clinicians carry out a comprehensive, medical diagnostic assessment in first-episode patients who are suspected of developing schizophrenia...
  5. ncbi The muddles of medicine: a practical, clinical addendum to the biopsychosocial model
    Oliver Freudenreich
    MGH Division of Psychiatry and Medicine, Boston, MA 02114, USA
    Psychosomatics 51:365-9. 2010
    ..The commonly-accepted "biopsychosocial model" does not always lend itself to the kind of pragmatic decisions that many clinical situations demand of physicians...
  6. ncbi Analysis of peripheral immune activation in schizophrenia using quantitative reverse-transcription polymerase chain reaction (RT-PCR)
    Oliver Freudenreich
    Schizophrenia Program, Massachusetts General Hospital, Boston, MA, United States
    Psychiatry Res 176:99-102. 2010
    ....
  7. ncbi Catatonic coma with profound bradycardia
    Oliver Freudenreich
    Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA
    Psychosomatics 48:74-8. 2007
    ....
  8. ncbi Risperidone augmentation for schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled trial
    Oliver Freudenreich
    Massachusetts General Hospital Schizophrenia Program, Freedom Trail Clinic, 25 Staniford St, 2nd Floor, Boston, MA 02114, USA
    Schizophr Res 92:90-4. 2007
    ..Risperidone augmentation of clozapine in refractory schizophrenia has theoretical but only inconsistent support from clinical trials...
  9. ncbi An approach to symptoms at the interface of medicine and psychiatry: pain, insomnia, weight loss and anorexia, fatigue and forgetfulness, and sexual dysfunction
    Oliver Freudenreich
    Harvard Medical School, 25 Shattuck Street, Boston, MA 02115, USA
    Med Clin North Am 94:1217-27, xi. 2010
    ..The management of a patient in whom no satisfactory medical or psychiatric diagnosis can be made is also reviewed briefly...
  10. ncbi Psychiatric treatment of persons with HIV/AIDS: an HIV-psychiatry consensus survey of current practices
    Oliver Freudenreich
    Freedom Trail Clinic, 25 Staniford, St, Boston, MA 02114, USA
    Psychosomatics 51:480-8. 2010
    ..Only sparse evidence from controlled clinical trials is available to guide the psychiatric treatment of persons with HIV/AIDS...
  11. ncbi The evaluation and management of patients with first-episode schizophrenia: a selective, clinical review of diagnosis, treatment, and prognosis
    Oliver Freudenreich
    The Department of Psychiatry, Harvard Medical School, Schizophrenia Program, Massachusetts General Hospital, Boston, MA 02114, USA
    Harv Rev Psychiatry 15:189-211. 2007
    ..We describe the illness course and the prognosis for this acute phase of illness and the immediate, postpsychotic period...
  12. ncbi Hepatitis C in schizophrenia: screening experience in a community-dwelling clozapine cohort
    Oliver Freudenreich
    Massachusetts General Hospital Schizophrenia Program, Freedom Trail Clinic, the Division of Infectious Diseases and Partners AIDS Research Center, and Harvard Medical School, Boston, MA 02114, USA
    Psychosomatics 48:405-11. 2007
    ..However, clinical experience treating HCV in schizophrenia patients is limited; in this cohort, 2 years after screening, no patient had received interferon/ribavirin treatment...
  13. ncbi Modafinil for clozapine-treated schizophrenia patients: a double-blind, placebo-controlled pilot trial
    Oliver Freudenreich
    Massachusetts General Hospital Schizophrenia Program, Freedom Trail Clinic, Boston, MA 02114, USA
    J Clin Psychiatry 70:1674-80. 2009
    ..Clozapine-induced sedation can worsen cognition and impair social and occupational functioning...
  14. ncbi A prototype approach toward antipsychotic medication adherence in schizophrenia
    Oliver Freudenreich
    Department of Psychiatry, Harvard Medical School, Boston, MA, USA
    Harv Rev Psychiatry 17:35-40. 2009
    ..In this scheme, drug attitude and worldview are key variables for adherence; both can be ascertained during the clinical interview and quantified with rating scales...
  15. ncbi Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients
    David C Henderson
    Schizophrenia Program, Massachusetts General Hospital, Boston, MA, USA
    J Clin Psychopharmacol 29:165-9. 2009
    ..087). The addition of aripiprazole to a stable dose of olanzapine was well tolerated and resulted in significant improvements on several outcome measures that predict risk for medical morbidity...
  16. ncbi Independent effects of tobacco abstinence and bupropion on cognitive function in schizophrenia
    A Eden Evins
    Schizophrenia Program, the Tobacco Treatment and Research Center, Massachusetts General Hospital, Boston, MA 02114, USA
    J Clin Psychiatry 66:1184-90. 2005
    ....
  17. ncbi Posttraumatic stress disorder, cognitive function and quality of life in patients with schizophrenia
    Xiaoduo Fan
    Schizophrenia Program, Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Psychiatry Res 159:140-6. 2008
    ..Evaluating PTSD in patients with schizophrenia could have important implications from both clinical and research perspectives...
  18. ncbi Waist circumference is the best anthropometric predictor for insulin resistance in nondiabetic patients with schizophrenia treated with clozapine but not olanzapine
    David C Henderson
    Schizophrenia Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    J Psychiatr Pract 15:251-61. 2009
    ....
  19. ncbi Dietary saturated fat intake and glucose metabolism impairments in nondiabetic, nonobese patients with schizophrenia on clozapine or risperidone
    David C Henderson
    Schizophrenia Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA USA
    Ann Clin Psychiatry 22:33-42. 2010
    ..The goal of this study was to understand the relationship between clozapine and risperidone with glucose and lipid metabolism and dietary fat intake in patients with schizophrenia...
  20. ncbi Ziprasidone as an adjuvant for clozapine- or olanzapine-associated medical morbidity in chronic schizophrenia
    David C Henderson
    Schizophrenia Program, Massachusetts General Hospital, Boston, Massachusetts, USA
    Hum Psychopharmacol 24:225-32. 2009
    ....
  21. ncbi A 12-week double-blind, placebo-controlled study of bupropion sr added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia
    A Eden Evins
    Schizophrenia Program, Massachusetts General Hospital, Boston, MA 02144, USA
    J Clin Psychopharmacol 27:380-6. 2007
    ....
  22. ncbi Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study
    David C Henderson
    Schizophrenia Program, MGH Weight Center, Massachusetts General Hospital, Boston, MA 02114, USA
    J Clin Psychiatry 66:1116-21. 2005
    ..The goal of this 10-year naturalistic study was to examine, in clozapine-treated patients, the change in cardiovascular risk factors following clozapine initiation and the mortality estimates from cardiovascular disease...
  23. ncbi Attitudes of schizophrenia outpatients toward psychiatric medications: relationship to clinical variables and insight
    Oliver Freudenreich
    MGH Schizophrenia Program, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston 02114, USA
    J Clin Psychiatry 65:1372-6. 2004
    ....
  24. ncbi Contribution of methylenetetrahydrofolate reductase (MTHFR) polymorphisms to negative symptoms in schizophrenia
    Joshua L Roffman
    Schizophrenia Research Program, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
    Biol Psychiatry 63:42-8. 2008
    ..We examined whether the methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C functional polymorphisms contribute to negative symptoms...
  25. ncbi High-dose galantamine augmentation inferior to placebo on attention, inhibitory control and working memory performance in nonsmokers with schizophrenia
    Michael A Dyer
    Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, United States
    Schizophr Res 102:88-95. 2008
    ..In summary, galantamine treatment, at a dose of 32 mg/day, was well tolerated but was not effective as an adjunctive treatment for cognitive deficits in stable nonsmokers with schizophrenia...
  26. ncbi A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia
    Donald C Goff
    Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Neuropsychopharmacology 33:465-72. 2008
    ..CX516 was not effective for cognition or for symptoms of schizophrenia when added to clozapine, olanzapine, or risperidone...
  27. ncbi Predictors of early abstinence in smokers with schizophrenia
    Melissa A Culhane
    Schizophrenia Research Program, Boston Addiction Research Program, Boston, USA
    J Clin Psychiatry 69:1743-50. 2008
    ..Identification of factors associated with abstinence may allow clinicians to optimize treatment prior to a smoking cessation attempt...
  28. ncbi A double-blind placebo-controlled trial of bupropion sustained-release for smoking cessation in schizophrenia
    A Eden Evins
    Schizophrenia Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA 012114, USA
    J Clin Psychopharmacol 25:218-25. 2005
    ..We conclude that bupropion does not worsen clinical symptoms of schizophrenia and is modestly effective for smoking cessation in patients with schizophrenia. The relapse rate is high after treatment discontinuation...
  29. ncbi Higher white blood cell counts are associated with an increased risk for metabolic syndrome and more severe psychopathology in non-diabetic patients with schizophrenia
    Xiaoduo Fan
    Schizophrenia Program, Department of Psychiatry, Massachusetts General Hospital, Boston, MA, United States
    Schizophr Res 118:211-7. 2010
    ..The present study examined whether white blood cell count (WBC), a marker of systemic inflammation, is associated with metabolic syndrome and psychiatric symptoms in non-diabetic patients with schizophrenia...
  30. ncbi Effects of modafinil on weight, glucose and lipid metabolism in clozapine-treated patients with schizophrenia
    David C Henderson
    Massachusetts General Hospital Schizophrenia Program, 25 Staniford Street, 2nd Floor, Boston, MA 02114, USA
    Schizophr Res 130:53-6. 2011
    ..Modafinil has been proposed as a treatment for clozapine-induced sedation and metabolic abnormalities...
  31. ncbi The effects of transdermal nicotine on cognition in nonsmokers with schizophrenia and nonpsychiatric controls
    Ruth S Barr
    The Schizophrenia Program of the Massachusetts General Hospital, Boston, MA 02114, USA
    Neuropsychopharmacology 33:480-90. 2008
    ..These results confirm previous findings that a single dose of nicotine improves attention and suggest that nicotine may specifically improve response inhibition in nonsmokers with schizophrenia...
  32. ncbi Dietary intake profile of patients with schizophrenia
    David C Henderson
    Massachusetts General Hospital Schizophrenia Program, Freedom Trail Clinic, Boston, MA, USA
    Ann Clin Psychiatry 18:99-105. 2006
    ..We performed a cross-sectional study evaluating the dietary intake of patients with schizophrenia or schizoaffective disorder treated with atypical antipsychotic agents...
  33. ncbi Glucose metabolism in patients with schizophrenia treated with olanzapine or quetiapine: a frequently sampled intravenous glucose tolerance test and minimal model analysis
    David C Henderson
    Schizophrenia Program, Massachusetts General Hospital, Boston, USA
    J Clin Psychiatry 67:789-97. 2006
    ..Much less is known regarding other agents such as quetiapine. The objective of this study was to compare matched olanzapine- and quetiapine-treated schizophrenia patients and normal controls on measures of glucose metabolism...
  34. ncbi No effect of single-dose intranasal insulin treatment on verbal memory and sustained attention in patients with schizophrenia
    Xiaoduo Fan
    Schizophrenia Program, Massachusetts General Hospital, Boston, MA, USA
    J Clin Psychopharmacol 31:231-4. 2011
    ..Whereas efficacy for cognition has not yet been established for any pharmacologic strategy in schizophrenia, an accumulating body of evidence suggests a possible beneficial role of insulin...
  35. ncbi Interactive effects of COMT Val108/158Met and MTHFR C677T on executive function in schizophrenia
    Joshua L Roffman
    Schizophrenia Program, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts 02129, USA
    Am J Med Genet B Neuropsychiatr Genet 147:990-5. 2008
    ..It is plausible that cumulative effects of the MTHFR T and COMT Val alleles on intracellular methylation profiles and prefrontal dopamine transmission underlie their interactive effect on perseverative errors...
  36. ncbi Elevated hemoglobin A1c as a possible indicator of diabetes mellitus and diabetic ketoacidosis in schizophrenia patients receiving atypical antipsychotics
    David C Henderson
    Schizophrenia Program, Department of Psychiatry, Massachusetts General Hospital, Boston, Mass, USA
    J Clin Psychiatry 68:533-41. 2007
    ..0-295.9; referred to as "schizophrenia patients" hereafter) treated with atypical antipsychotic agents...
  37. ncbi Higher fasting serum insulin is associated with increased resting energy expenditure in nondiabetic schizophrenia patients
    Xiaoduo Fan
    Schizophrenia Program, Department of Psychiatry, Massachusetts General Hospital Harvard Medical School, Boston, Massachusetts 02114, USA
    Biol Psychiatry 60:1372-7. 2006
    ..This study examined the relationship between fasting serum insulin level and resting energy expenditure (REE) in a cross-sectional sample of nondiabetic schizophrenia patients...
  38. ncbi Strategies for improving treatment adherence in schizophrenia and schizoaffective disorder
    Donald C Goff
    Schizophrenia Program, Harvard Medical School and Massachusetts General Hospital, Boston, MA, USA
    J Clin Psychiatry 71:20-6. 2010
    ....
  39. ncbi Sexual functioning, psychopathology and quality of life in patients with schizophrenia
    Xiaoduo Fan
    Schizophrenia Program, Department of Psychiatry, Massachusetts General Hospital, Boston, MA, United States
    Schizophr Res 94:119-27. 2007
    ..The present study was to characterize relationships among sexual functioning, schizophrenia symptoms and quality of life measures. In addition, sexual functioning was compared among patients treated with different antipsychotic agents...
  40. ncbi Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists
    Donald C Goff
    Schizophrenia Program, Massachusetts General Hospital, Boston, MA 02114, USA
    J Clin Psychiatry 66:183-94; quiz 147, 273-4. 2005
    ..Psychiatrists should address this problem by adopting established strategies for prevention and intervention...
  41. ncbi Effects of the methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism on executive function in schizophrenia
    Joshua L Roffman
    Schizophrenia Research Program, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, USA
    Schizophr Res 92:181-8. 2007
    ..This study examined whether schizophrenia patients homozygous for the risk allele (T/T) exhibit greater impairment in executive function, and determined the extent to which MTHFR's effects on negative symptoms underlie this relationship...
  42. ncbi Placebo-controlled pilot study of ramelteon for adiposity and lipids in patients with schizophrenia
    Christina P C Borba
    Schizophrenia Program, Massachusetts General Hospital, Boston, MA, USA
    J Clin Psychopharmacol 31:653-8. 2011
    ..We now report a randomized placebo-controlled pilot study to examine the effects of ramelteon on obesity and metabolic disturbances among subjects with schizophrenia...
  43. ncbi A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain
    David C Henderson
    Schizophrenia Program, Weight Center, Endocrine Unit, and Biostatistics Center, Massachusetss General Hospital, Boston, USA
    Am J Psychiatry 162:954-62. 2005
    ..This study examined the effectiveness of sibutramine, an approved weight loss agent, in overweight and obese subjects taking olanzapine for schizophrenia or schizoaffective disorder...
  44. ncbi Added donepezil for stable schizophrenia: a double-blind, placebo-controlled trial
    Oliver Freudenreich
    MGH Schizophrenia Program, Freedom Trail Clinic, Boston, MA 02114, USA
    Psychopharmacology (Berl) 181:358-63. 2005
    ..A donepezil add-on strategy might make sense in selected schizophrenia cases where a pathological process is known to affect cholinergic neurons (e.g., history of head injury or comorbid dementia)...
  45. ncbi Impact of integrated and measurement-based depression care: clinical experience in an HIV clinic
    Shane M Coleman
    Department of Psychiatry, Harvard Medical School, Boston, MA, USA
    Psychosomatics 53:51-7. 2012
    ..While randomized trials have shown the efficacy of treatment for depression in HIV/AIDS, the implementation of evidence-based treatments in real-world settings remains a challenge...
  46. ncbi A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients
    Donald C Goff
    Schizophrenia Program, Massachusetts General Hospital, Boston, Mass, USA
    Psychopharmacology (Berl) 179:144-50. 2005
    ..The strongest evidence for efficacy has come from studies using D-cycloserine at a dose of 50 mg/day added to conventional antipsychotics in trials of 8 weeks duration or less...
  47. ncbi Elevated serum levels of C-reactive protein are associated with more severe psychopathology in a subgroup of patients with schizophrenia
    Xiaoduo Fan
    Schizophrenia Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
    Psychiatry Res 149:267-71. 2007
    ..An inflammatory process, as reflected by elevated serum levels of CRP, might be associated with more severe psychopathology in a subgroup of patients with schizophrenia...
  48. ncbi Clozapine: key discussion points for prescribers
    Michele Hill
    MGH Schizophrenia Clinical and Research Program, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Clin Schizophr Relat Psychoses 6:177-85. 2013
    ..This article reviews the literature on clozapine in order to measure its potential effectiveness against its adverse effects and ultimately aims to serve as a useful summary for clinicians in their everyday prescribing...
  49. ncbi Ownership, responsibility and hospital care: lessons for the consultation psychiatrist
    Nicholas Kontos
    Department of Psychiatry, Cambridge Health Alliance, Harvard Medical School, Cambridge, MA 02139, USA
    Gen Hosp Psychiatry 30:257-62. 2008
    ..To identify scenarios in which consultation psychiatrists encounter difficulty reconciling their clinical role with consultees' expectations and to suggest concepts that help navigate these situations...
  50. ncbi Fatigue in psychiatric HIV patients: a pilot study of psychological correlates
    Johanna Paddison
    Division of Psychiatry and Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Psychosomatics 50:455-60. 2009
    ..Even though viral management of HIV infection is now more effective, clinical observations suggest that fatigue remains a problem for a substantial proportion of patients...
  51. ncbi Impact of a metabolic screening bundle on rates of screening for metabolic syndrome in a psychiatry resident outpatient clinic
    Ilse R Wiechers
    Dept of Psychiatry, Massachusetts General Hospital, Boston, USA
    Acad Psychiatry 36:118-21. 2012
    ....
  52. ncbi Treatment adherence in schizophrenia and schizoaffective disorder
    Donald C Goff
    Schizophrenia Program, Massachusetts General Hospital and Harvard Medical School, Boston, USA
    J Clin Psychiatry 72:e13. 2011
    ..Depot antipsychotics can improve adherence and provide the clinician with reliable information about the dosage of medication received for purposes of dose adjustments or to guide response to relapse...
  53. ncbi Two-year follow-up of a smoking cessation trial in patients with schizophrenia: increased rates of smoking cessation and reduction
    A Eden Evins
    Harvard Medical School and the Schizophrenia Research Program, Massachusetts General Hospital, Freedom Trail Clinic, 25 Staniford Street, Boston, MA 02114, USA
    J Clin Psychiatry 65:307-11; quiz 452-3. 2004
    ....
  54. ncbi The consultation psychiatrist as effective physician
    Nicholas Kontos
    Department of Psychiatry, Cambridge Health Allilance, Harvard Medical School, Cambridge, MA, USA
    Gen Hosp Psychiatry 25:20-3. 2003
    ..These principles emphasize the medical model, the status of the psychiatrist as a medical expert, and the importance of defining one's professional limits...
  55. ncbi Dysfunction of a cortical midline network during emotional appraisals in schizophrenia
    Daphne J Holt
    Athinoula A Martinos Center for Biomedical Imaging, Charlestown, MA, USA
    Schizophr Bull 37:164-76. 2011
    ..These findings suggest that impaired functioning of cortical midline structures in schizophrenia may underlie faulty interpretations of social events, contributing to delusion formation...
  56. ncbi Clozapine use in HIV-infected schizophrenia patients: a case-based discussion and review
    Shamim Hashemi Nejad
    Division of Psychiatry and Medicine, Massachusetts General Hospital, Boston, MA 02114, USA
    Psychosomatics 50:626-32. 2009
    ..However, 20% to 30% of patients with schizophrenia are refractory to first-line antipsychotics...
  57. ncbi Interferon-induced psychosis as a "psychiatric contraindication" to hepatitis C treatment: a review and case-based discussion
    Benjamin C Silverman
    Wang Ambulatory Care Center, Massachusetts General Hospital, 15 Parkman St, Boston, MA 02114, USA
    Psychosomatics 51:1-7. 2010
    ..Interferon-based treatments have the potential to decrease the burden of disease, but are complicated by side effects, including neuropsychiatric symptoms...
  58. ncbi Folate, homocysteine, and negative symptoms in schizophrenia
    Donald C Goff
    Schizophrenia Program and Neurology Service, Massachusetts General Hospital, Boston, USA
    Am J Psychiatry 161:1705-8. 2004
    ....
  59. ncbi Focus on polypharmacy in schizophrenia: does anyone truly benefit?
    Donald C Goff
    Schizophrenia Program, Massachusetts General Hospital, Boston, MA, USA
    Int J Neuropsychopharmacol 7:109-11. 2004
  60. ncbi Assessing clinicians' management of first episode schizophrenia using clinical case vignettes
    Jeff C Huffman
    Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts, USA
    Early Interv Psychiatry 4:31-8. 2010
    ..Clinical case vignettes with free-form responses can be used to carefully assess whether front line practitioners provide guideline-adherent management of first episode psychosis...
  61. ncbi Elevated clozapine serum level after treatment with amiodarone
    Jonathan R Stevens
    Dept. of Psychiatry, Massachusetts General Hospital, MA 02114, USA
    Psychosomatics 49:255-7. 2008
  62. ncbi Optimizing outcome with antipsychotic treatment in first-episode schizophrenia: balancing efficacy and side effects
    Oliver Freudenreich
    Department of Psychiatry, Harvard Medical School, Massachusetts General Hospital, Boston, MA
    Clin Schizophr Relat Psychoses 6:115-21. 2012
    ....
  63. ncbi Schizophrenia for primary care providers: how to contribute to the care of a vulnerable patient population
    Mark Viron
    Massachusetts General Hospital Schizophrenia Program, Boston, USA
    Am J Med 125:223-30. 2012
    ....
  64. ncbi Depressogenic effects of medications: a review
    Christopher M Celano
    Harvard Medical School, Boston, Massachusetts, USA
    Dialogues Clin Neurosci 13:109-25. 2011
    ....
  65. ncbi Fronto-hippocampal function during temporal context monitoring in schizophrenia
    Anthony P Weiss
    Department of Psychiatry, Massachusetts General Hospital, Boston, MA 02129, USA
    Biol Psychiatry 60:1268-77. 2006
    ..Given the importance of the hippocampus and prefrontal cortex (PFC) in this type of memory, we hypothesized that this cognitive deficit stemmed from aberrant fronto-hippocampal activation during memory retrieval...
  66. ncbi Management of psychosis associated with a prolactinoma: case report and review of the literature
    Shirin Ali
    McLean Hospital, Boston, MA, USA
    Psychosomatics 51:370-6. 2010
    ..Psychosis is treated with dopamine-receptor blockers that may result in elevated serum prolactin and symptomatic hyperprolactinemia...
  67. ncbi Clinical experience with the management of schizophrenia in the general hospital
    Oliver Freudenreich
    Massachusetts General Hospital Schizophrenia Program, Harvard Medical School, Boston, MA 02114, USA
    Psychosomatics 44:12-23. 2003
    ..In addition to conducting conventional consultations, the consultation psychiatrist in such cases often has a role in educating hospital staff about schizophrenia and in serving as a physician for the mentally ill...
  68. ncbi Drug-induced sialorrhea
    Oliver Freudenreich
    Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Drugs Today (Barc) 41:411-8. 2005
    ..g., sublingual ipratropium spray); or increase adrenergic tone (e.g., clonidine patch). Recently, botulinum injections into the parotid gland have been used successfully to treat refractory cases...
  69. ncbi Treatment noncompliance with orally disintegrating olanzapine tablets
    Oliver Freudenreich
    Can J Psychiatry 48:353-4. 2003
  70. ncbi Polypharmacy in schizophrenia: a fuzzy concept
    Oliver Freudenreich
    J Clin Psychiatry 64:1132; author reply 1132-3. 2003
  71. ncbi Exacerbation of idiopathic priapism with risperidone-citalopram combination
    Oliver Freudenreich
    J Clin Psychiatry 63:249-50. 2002
  72. ncbi Using a medical model with psychotic patients
    Nicholas Kontos
    Am J Psychiatry 163:1646-7; author reply 1647. 2006
  73. ncbi A successful antipsychotic combination trial. Quo Vadis?
    Stephen Stahl
    Acta Psychiatr Scand 110:241-2. 2004
  74. ncbi Stimulant misuse in college for "pseudo-attention deficit disorder" during schizophrenia prodrome
    Oliver Freudenreich
    Am J Psychiatry 163:2019. 2006
  75. ncbi Clozapine-induced sialorrhea treated with sublingual ipratropium spray: a case series
    Oliver Freudenreich
    J Clin Psychopharmacol 24:98-100. 2004
  76. ncbi On biology, phenomenology, and pharmacology in schizophrenia
    Oliver Freudenreich
    Am J Psychiatry 161:376; author reply 377-8. 2004
  77. ncbi The ABCs of suicide
    Oliver Freudenreich
    J Clin Psychiatry 66:1194-5. 2005
  78. ncbi Checklist psychiatry's effect on psychiatric education
    Oliver Freudenreich
    Am J Psychiatry 161:930; author reply 930. 2004